HPLC Monitoring of Malondialdehyde in Patients with Endometrial and Ovarial Cancer

Page: 375

J. Matějčkováa, M. Samecb, M. Jačeka, and P. Tůmaa

a Department of Biochemistry, Molecular and Cell Biology, Third Faculty od Medicine, Charles University, Prague, b Department of Gynaecology and Obstetrics, Faculty Hospital Královské Vinohrady, Prague

 

A method for determination of malondialdehyde (MDA) as the major biomarker of oxidative damage of cellular membranes was developed. MDA was transformed to its 2,4-dinitrophenylhydrazone, which was then separated by HPLC. The LOD and repeatability of the method is satisfactory for monitoring MDA in blood plasma. The performed clinical study revealed systematically enhanced MDA levels in patients with gynaecological carcinoma in comparison with the control group.

 

Full text (PDF)